The observed improvements in cytotoxicity, reduced exhaustion, and enhanced in vivo persistence of NKG2D/CD28&CAR-T cells highlight their potential as a valuable approach in cancer immunotherapy. This evidence concerns the gene KLRK1 and cancer.